NGS revenue guidance was raised to $205 million to $209 million, reflecting 21%-24% growth. Biopharma revenue was guided to $23 million for fiscal 2025, representing 13% year-over-year growth.

Despite Reddit's strong fundamentals and network effects, valuation appears 50% too high. Learn why RDDT stock is a Sell.

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...

The European Commission has published on the 29th January the “Competitiveness Compass for the EU”, setting out ambitious initiatives aimed ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

We recently published a list of Top 10 Trending AI Stocks on Latest News. In this article, we are going to take a look at ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Bio-Plastic Market. The global bio-plastic market is witnessing a remarkable transformation as industries and consumers ...

This tobacco company offers value investors a great entry point and a rich 7.84% dividend. Altria Group Inc. (NYSE: MO) ...

The global 3D bio-printing market is set for extraordinary growth ... statistical data models for pricing analysis, ...